Won-Ki Cho
Presidente presso CHOA PHARMACEUTICAL CO., LTD.
Patrimonio netto: 4 M $ in data 30/04/2024
Profilo
Won-Ki Cho is currently the Chairman of ChoA Pharmaceutical Co., Ltd.
and Medipharm.
He has an undergraduate degree from Pusan National University and Kyungpook National University, and a doctorate degree from Pukyong National University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2023 | 3 464 843 ( 11.18% ) | 4 M $ | 30/04/2024 |
Posizioni attive di Won-Ki Cho
| Società | Posizione | Inizio |
|---|---|---|
| CHOA PHARMACEUTICAL CO., LTD. | Presidente | 01/01/1988 |
Medipharm
 Medipharm Medical DistributorsDistribution Services Medipharm, founded in 2015, is a cannabis concentrate and derivative product manufacturer based in Seongnam, South Korea. The South Korean company has a good manufacturing practices certified facility with ISO standard-built clean rooms and five primary extraction lines for delivering pure and precision-dosed cannabis products. Medipharm invests in research-driven teams, state-of-the-art technology, and downstream purification methodologies to formulate, develop, process, package, and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. The CEO of the private company is Sung-Hwan Cho. | Presidente | - |
Formazione di Won-Ki Cho
| Pusan National University | Undergraduate Degree |
| Pukyong National University | Doctorate Degree |
| Kyungpook National University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CHOA PHARMACEUTICAL CO., LTD. | Health Technology |
| Aziende private | 1 |
|---|---|
Medipharm
Medipharm Medical DistributorsDistribution Services Medipharm, founded in 2015, is a cannabis concentrate and derivative product manufacturer based in Seongnam, South Korea. The South Korean company has a good manufacturing practices certified facility with ISO standard-built clean rooms and five primary extraction lines for delivering pure and precision-dosed cannabis products. Medipharm invests in research-driven teams, state-of-the-art technology, and downstream purification methodologies to formulate, develop, process, package, and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. The CEO of the private company is Sung-Hwan Cho. | Distribution Services |
- Borsa valori
- Insiders
- Won-Ki Cho
